||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about Bespak (London Stock Exchange): 0 recent articles
|grupo guitarlumber: (Repeating to clarify nature of deal, adds share price other background)
LONDON (AFX) - Bespak PLC said the European Medicines Evaluation Agency had
accepted a filing by Pfizer Inc and Aventis SA who are both seeking rights to
market Exubera, a diabetes treatment which is inhaled in powdered form.
Bespak said it will manufacture the drug delivery device under an
arrangement with Nektar Therapeutics, Inc, a US company which developed both
Exubera and the means of delivering it.
In a statement, Bespak said the timing of full scale production is as yet
unknown and will depend in part on the speed of the regulatory review process.
Pfizer and Aventis are seeking approval to market Exubera to adult patients
with Type 1 and Type 2 diabetes.
At 8.20 am Bespak was among the best performing small-cap stocks in the
London market, gaining 22-1/2 pence, or 4.2 pct, to 557-1/2.
|daycase1: * Medical devices company Bespak’s (BPK) non-executive director William Meredith has been shopping on the other side of the Atlantic as he picked up 5,000 American Depository Receipts on Wednesday at $7.50 (523p). His £26,130 payout doubles his holding in the company to 10,000 ADRs.
Meredith has pounced while Bespak’s share price is struggling close to its year-low. It began the year in sprightly fashion at a high of 590p but fell gradually until it hit 500p last week. After a brief rally it has stalled and today closed down 1p at 504p.
In January the company reported record sales in the six months to 2 November of £42.9 million, up from £40.4 million the previous year. However pre-tax profits slipped from £7.8 million to £7.2 million after higher research and development costs.|
Bespak share price data is direct from the London Stock Exchange